(Q24248046)

30 July 2017

1 reference

title

Oral beta-blockers for mild to moderate hypertension during pregnancy (English)

1 reference

30 July 2017

0 references

arterial hypertension

1 reference

2

1 reference

30 July 2017

1

Laura Magee

0 references

author name string

L A Magee

series ordinal

1

1 reference

30 July 2017

publication date

21 July 2003

0 references

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

30 July 2017

published in

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

CD002863

1 reference

Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

First year of life after the use of atenolol in pregnancy associated hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

Atenolol in essential hypertension during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

Short-term metabolic effects of isradipine and metoprolol in pre-eclampsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

Flow velocity analysis of umbilical and uterine artery flow in pre‐eclampsia treated with propranolol or pindolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

Glycemia in newborns of hypertensive mothers according to maternal treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

The detection, investigation and management of hypertension in pregnancy: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

An assessment of clinically useful measures of the consequences of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

Management of severe, early pre-eclampsia: is conservative management justified?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

Management of pregnancy-induced hypertension with pindolol--comparative study with methyldopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Uterine and fetal hemodynamics and fetal cardiac function after atenolol and pindolol infusion. A randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Atenolol and fetal growth in pregnancies complicated by hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Relationship between renal histology and plasma antithrombin III activity in women with early onset preeclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Use of labetalol and methyldopa in pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Preeclampsia: haemostatic status and the short-term effects of methyldopa and isradipine therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Atenolol in essential hypertension during pregnancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Intrauterine exposure to the beta-adrenergic receptor-blocking agent metoprolol and allergy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

A prospective controlled trial of metoprolol-hydralazine treatment in hypertension during pregnancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002863

7 January 2021

10.1002/14651858.CD002863

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

30 July 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

12917933

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference